Product image of Letrozole Almus (Letrozole) supplied by GNH India

Letrozole Almus

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Almus (Letrozole)

Letrozole, the active ingredient in Letrozole Almus, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to lower estrogen levels and treat hormone receptor‑positive breast cancer in postmenopausal women and may be used as part of adjuvant therapy after surgery.

GNH India supplies Letrozole Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides bulk and packaged quantities to hospitals, pharmacies and procurement teams across global markets.

Manufacturer / TM Owner

Almus France

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

  • Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor growth by lowering estrogen levels.
  • Adjuvant therapy for early‑stage breast cancer: decreases risk of recurrence after surgery.
  • Metastatic breast cancer (postmenopausal): helps control disease progression in advanced cases.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme (CYP19A1) in peripheral tissues, blocking the conversion of androstenedione and testosterone to estrone and estradiol. By inhibiting this key step in estrogen biosynthesis, systemic estrogen concentrations fall, depriving estrogen‑dependent tumor cells of a growth stimulus. The effect is dose‑dependent and persists for the duration of therapy while the drug is present in plasma.

Side Effects

Letrozole may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Joint or muscle pain: arthralgia or myalgia.
  • Fatigue: persistent tiredness.
  • Nausea: mild to moderate upset stomach.
  • Headache: occasional throbbing pain.
  • Increased cholesterol: elevated lipid levels.

Serious or Rare Side Effects

  • Osteoporosis or bone fractures: reduced bone mineral density.
  • Severe liver injury: elevated transaminases or hepatitis.
  • Deep vein thrombosis or pulmonary embolism: clot formation in veins.
  • Allergic reactions: rash, itching, swelling, or anaphylaxis.

Precautions & Warnings

Before initiating Letrozole, clinicians should consider several safety considerations.

  • Pregnancy contraindication: drug is classified Category X and must not be used in pregnant women.
  • Breastfeeding restriction: not recommended for nursing mothers due to potential drug transfer.
  • Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation.
  • Cardiovascular risk: evaluate lipid profile and manage hypercholesterolemia.
  • Drug interactions: review concomitant medications that affect CYP2A6 or estrogen levels.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma levels.
  • Estrogen‑containing hormone therapy: antagonizes therapeutic effect.
  • Tamoxifen: combined use may reduce effectiveness of both agents.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may enhance anticoagulant effect, monitor INR.
  • Lipid‑lowering agents (statins): possible additive effect on liver enzymes.
  • CYP2A6 inducers (rifampin): may lower letrozole concentrations, reduce efficacy.

Frequently Asked Questions

Letrozole Almus is prescribed to treat hormone receptor‑positive breast cancer in postmenopausal women. It is used as adjuvant therapy after surgery to lower the risk of recurrence and also for managing metastatic disease when cancer has spread beyond the breast.

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, estrogen levels drop, depriving estrogen‑dependent tumor cells of a key growth signal and slowing cancer progression.

The specific dose of Letrozole Almus is determined by the prescribing physician based on the patient’s clinical condition, treatment stage and individual factors. Healthcare providers follow established guidelines but set the exact regimen for each patient.

Letrozole is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and affect the infant.

To request Letrozole Almus, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor with a high potency and a long half‑life, offering consistent estrogen suppression. Compared with earlier agents such as anastrozole, letrozole often provides stronger estrogen reduction, which may translate into improved disease control in certain patient populations.

Letrozole Almus tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Letrozole Almus is taken orally, usually as a whole tablet with water. It is generally administered once daily, at the same time each day, and can be taken with or without food according to the prescriber’s instructions.

Serious risks include osteoporosis or bone fractures due to reduced estrogen, severe liver injury, and rare clotting events such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored regularly for bone health, liver function and any signs of abnormal clotting.

Letrozole Almus should not be used by pregnant women, nursing mothers, or individuals with known hypersensitivity to letrozole or any component of the formulation. It is also contraindicated in patients with severe liver impairment or uncontrolled osteoporosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT